This article has been updated from an earlier version with additional information from Qiagen on its PMA filing for an EGFR mutation companion test.
A race commenced this week between Boehringer Ingelheim and Roche to launch the first pharmacogenetically targeted EGFR inhibitor for non-small cell lung cancer in the US market.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
